Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764444 | 0.91 | PDE2A (0.70) | PDE2AHTR1ANT5EADORA2AADORA2B | |
| SCHEMBL11420439 | 0.90 | PDE2A (0.61) | PDE2AHTR1AADORA2AADORA2BBCHE | |
| SCHEMBL11427985 | 0.87 | PDE2A (0.64) | PDE2AHTR1ANT5EADORA2AADORA2B | |
| SCHEMBL5961364 | 0.87 | PDE2A (0.64) | PDE2AHTR1ANT5EADORA2AADORA2B | |
| SCHEMBL6306348 | 0.86 | PDE2A (0.61) | PDE2AHTR1ANT5EADORA2AADORA2B | |
| SCHEMBL6306351 | 0.86 | PDE2A (0.61) | PDE2AHTR1ANT5EADORA2AADORA2B | |
| SCHEMBL11121799 | 0.83 | PDE2A (0.59) | PDE2AHTR1ANT5EADORA2AADORA2B | |
| SCHEMBL6293320 | 0.83 | HTR1A (0.56) | PDE2AHTR1ABCHE | |
| SCHEMBL9097705 | 0.82 | PDE2A (0.70) | PDE2AHTR1ANT5ELMNABCHE | |
| SCHEMBL11126005 | 0.81 | PDE2A (0.56) | PDE2AHTR1AADORA2AADORA2BBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6073087-A | — | — | None | — | — | JP | disclosed |
| JP-7138280-A | — | — | None | — | — | JP | disclosed |
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MANAGEMENT GMBH & CO. KG (DE) | 2012-08-30 | — | — | US | disclosed |
| EP-2430032-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | Alcafleu Management GmbH & Co. KG (DE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130778-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MANAGEMENT GMBH & CO. KG (DE) | 2010-11-18 | — | — | WO | disclosed |
| EP-0578208-B1 | Process for the preparation of 2-fluoro-9-(2,3,5-tri-O-benzyl-beta-arabinofuranozyl)adenine | ASH STEVENS INC (US) | 1995-12-27 | — | — | EP | disclosed |
| JP-H07138280-A | PRODUCTION OF 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE | ASH STEVENS INC | 1995-05-30 | — | — | JP | disclosed |
| US-5296589-A | Dissolving in nonreactive solvent, reacting with hydrogen, palladium chloride, hydrochloric acid in sealed vessel at elevated pressure, removing palladium chloride, neutralizing, separating product | ASH STEVENS, INC. (US) | 1994-03-22 | — | — | US | disclosed |
| JP-H0673087-A | IMPROVED METHOD | ASH STEVENS INC | 1994-03-15 | — | — | JP | disclosed |
| EP-0578208-A1 | Process for the preparation of 2-fluoro-9-(2,3,5-tri-O-benzyl-beta-arabinofuranozyl)adenine | ASH STEVENS, INC. (US) | 1994-01-12 | — | — | EP | disclosed |
| US-5252540-A | Herbicides | BASF AKTIENGESELLSCHAFT (DE) | 1993-10-12 | — | — | US | disclosed |
| US-5180824-A | 6-AZIDO-2-FLUOROPURINE, USEFUL IN THE SYNTHESIS OF NUCLEOSIDES | BERLEX BIOSCIENCES INC. (US) | 1993-01-19 | — | — | US | disclosed |
| US-4210745-A | Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | CD38, FLAD1, GART | PDE2A 4458/4885HTR1A 3247/4885NT5E 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.